Safety and efficacy of commonly used antimicrobial agents in the treatment of enterococcal infections: a review
暂无分享,去创建一个
[1] Tsutomu Kobayashi,et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction , 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[2] Hsin-Yi Lin,et al. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis , 2014, BMC Infectious Diseases.
[3] H. Cox,et al. 32 – Linezolid and Other Oxazolidinones , 2015 .
[4] G. Patel,et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. , 2010, Clinical therapeutics.
[5] C. Arias,et al. Enterococcus Species, Streptococcus gallolyticus Group, and Leuconostoc Species , 2015 .
[6] M. Zervos,et al. Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia. , 2015, Clinical therapeutics.
[7] M. Crespo,et al. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. , 2003, The Journal of antimicrobial chemotherapy.
[8] M. Falagas,et al. Linezolid for the Treatment of Patients with Central Nervous System Infection , 2007, The Annals of pharmacotherapy.
[9] Piet Claus,et al. Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. , 2006, European heart journal.
[10] M. Steed,et al. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Michael Barras,et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. , 2010, The Clinical biochemist. Reviews.
[12] Yen-Hung Lin,et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. , 2006, International journal of antimicrobial agents.
[13] S. Miyakis,et al. Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia , 2013, Antimicrobial Agents and Chemotherapy.
[14] H. Bundgaard,et al. Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study , 2012, European Journal of Clinical Microbiology & Infectious Diseases.
[15] L. Baddour,et al. Vancomycin-Resistant Enterococcus faecalis Endocarditis: Linezolid Failure and Strain Characterization of Virulence Factors , 2006, Journal of Clinical Microbiology.
[16] P. Cardona,et al. Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum , 1996, Antimicrobial agents and chemotherapy.
[17] E. López García,et al. [Enterococcal endocarditis]. , 1957, Revista clinica espanola.
[18] W. G. Maccallum,et al. A CASE OF ACUTE ENDOCARDITIS CAUSED BY MICROCOCCUS ZYMOGENES (NOV. SPEC.), WITH A DESCRIPTION OF THE MICROORGANISM , 1899, The Journal of experimental medicine.
[19] M. Zervos,et al. Endocarditis Caused by Resistant Enterococcus: An Overview , 2013, Current Infectious Disease Reports.
[20] Ian E. Alexander,et al. Fibroblasts Can Be Genetically Modified to Produce Excitable Cells Capable of Electrical Coupling , 2005, Circulation.
[21] Y. Chuang,et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. , 2010, Diagnostic microbiology and infectious disease.
[22] L. Friedrich,et al. Daptomycin in the treatment of bacteremia. , 2007, The American journal of medicine.
[23] L. Friedrich,et al. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). , 2009, International journal of antimicrobial agents.
[24] D. Maki,et al. Enterococcal Bacteremia: Clinical Features, the Risk of Endocarditis, and Management , 1988, Medicine.
[25] K. Gould,et al. Clinical update on linezolid in the treatment of Gram-positive bacterial infections , 2012, Infection and drug resistance.
[26] Á. Soriano,et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections , 2007, European Journal of Clinical Microbiology & Infectious Diseases.
[27] R. Moellering. Emergence of Enterococcus as a significant pathogen. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] P. Linden. Optimizing therapy for vancomycin-resistant enterococci (VRE). , 2007, Seminars in respiratory and critical care medicine.
[29] C. Urban,et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] H. Derendorf,et al. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin , 2010, European journal of medical research.
[31] Jerome J. Schentag,et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] G. Bearman,et al. Central nervous system infections due to vancomycin-resistant enterococci: case series and review of the literature. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[33] M. S. Lee,et al. Linezolid-associated toxic optic neuropathy. , 2006, Neurology.
[34] Vance G Fowler,et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. , 2006, The New England journal of medicine.
[35] J. Ariza,et al. Pilot Study of Ampicillin-Ceftriaxone Combination for Treatment of Orthopedic Infections Due to Enterococcus faecalis , 2009, Antimicrobial Agents and Chemotherapy.
[36] M. Dowzicky. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009. , 2011, Clinical therapeutics.
[37] V. Cattoir,et al. Genomic Analysis of Reduced Susceptibility to Tigecycline in Enterococcus faecium , 2014, Antimicrobial Agents and Chemotherapy.
[38] R. Arbeit,et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] H. Derendorf,et al. Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline , 2009, Clinical pharmacokinetics.
[40] R. Sodian,et al. Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens , 2010, Infection and drug resistance.
[41] Ronald N. Jones,et al. Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 , 2012, Antimicrobial Agents and Chemotherapy.
[42] L. Friedrich,et al. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. , 2007, The American journal of medicine.
[43] Arjun Srinivasan,et al. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010 , 2013, Infection Control & Hospital Epidemiology.
[44] M. Rybak,et al. Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model. , 2000, The Journal of antimicrobial chemotherapy.
[45] C. Finch,et al. Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. , 2012, Journal of hospital medicine.
[46] M. Zervos,et al. Clinical manifestations of enterococcal infection , 1990, European Journal of Clinical Microbiology and Infectious Diseases.
[47] G. Noskin,et al. Postoperative vancomycin-resistant Enterococcus faecium endophthalmitis. , 2007, Archives of ophthalmology.
[48] J. Bennett,et al. MANDELL, DAUGLAS AND BENNETT'S PRINCIPLES AND PRACTICE OF INFECTIOUS DISEASE , 2012 .
[49] K. Rolston,et al. Daptomycin use in neutropenic patients with documented gram-positive infections , 2013, Supportive Care in Cancer.
[50] M. Zervos,et al. High-level resistance to gentamicin in Streptococcus faecalis: risk factors and evidence for exogenous acquisition of infection. , 1986, The Journal of infectious diseases.
[51] C. Arias,et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[52] M. Schintler,et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. , 2010, The Journal of antimicrobial chemotherapy.
[53] L. Miller,et al. Systematic Review and Meta-Analysis of Linezolid and Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bloodstream Infections , 2013, Antimicrobial Agents and Chemotherapy.
[54] J. Yombi,et al. TIGECYCLINE-INDUCED ACUTE PANCREATITIS: ABOUT TWO CASES AND REVIEW OF THE LITERATURE , 2012, Acta clinica Belgica.
[55] J. Le,et al. Treatment of Meningitis Caused by Vancomycin-Resistant Enterococcus faecium: High-Dose and Combination Daptomycin Therapy , 2010, The Annals of pharmacotherapy.
[56] M. Gilmore,et al. Enterococcal Infection—Treatment and Antibiotic Resistance -- Enterococci: From Commensals to Leading Causes of Drug Resistant Infection , 2014 .
[57] Ronald N. Jones,et al. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). , 2014, International journal of antimicrobial agents.
[58] S. Zimmer,et al. Peripheral neuropathy associated with prolonged use of linezolid. , 2004, The Lancet. Infectious diseases.
[59] M. Rybak,et al. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. , 2015, The Journal of antimicrobial chemotherapy.
[60] D. Levine,et al. Vancomycin: a history. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[61] C. Arias,et al. Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), Lipopeptides (Daptomycin), and Lipoglycopeptides (Telavancin) , 2015 .
[62] C. Cabellos,et al. Enterococcal Meningitis: A Clinical Study of 39 Cases and Review of the Literature , 2003, Medicine.
[63] A. MacGowan,et al. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. , 2003, The Journal of antimicrobial chemotherapy.
[64] M. Maley,et al. Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia. , 2014, The Journal of antimicrobial chemotherapy.
[65] J. De La Torre,et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[66] G. Martinelli,et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[67] Allan R Tunkel,et al. Practice guidelines for the management of bacterial meningitis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[68] Brian T. Tsuji,et al. Ampicillin Enhances Daptomycin- and Cationic Host Defense Peptide-Mediated Killing of Ampicillin- and Vancomycin-Resistant Enterococcus faecium , 2011, Antimicrobial Agents and Chemotherapy.
[69] You-ning Liu,et al. Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease , 2010, Antimicrobial Agents and Chemotherapy.
[70] C. Hamilton,et al. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. , 2007, Diagnostic microbiology and infectious disease.
[71] D. Herr,et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] Brian T. Tsuji,et al. Linezolid‐Associated Peripheral and Optic Neuropathy, Lactic Acidosis, and Serotonin Syndrome , 2007, Pharmacotherapy.
[73] C. Arias,et al. Transferable Plasmid-Mediated Resistance to Linezolid Due to cfr in a Human Clinical Isolate of Enterococcus faecalis , 2012, Antimicrobial Agents and Chemotherapy.
[74] Carmen Torres,et al. Brief Communication: Treatment of Enterococcus faecalis Endocarditis with Ampicillin plus Ceftriaxone , 2007, Annals of Internal Medicine.
[75] V. Mave,et al. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? , 2007, The Journal of antimicrobial chemotherapy.
[76] S. Grim,et al. Safety of linezolid in patients with baseline thrombocytopenia. , 2008, The Journal of antimicrobial chemotherapy.
[77] R. Holliman,et al. HIGH-LEVEL GENTAMICIN RESISTANCE IN STREPTOCOCCUS FAECALIS , 1988, The Lancet.
[78] C. Arias,et al. Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci. , 2014, International journal of antimicrobial agents.
[79] B. Murray. The life and times of the Enterococcus , 1990, Clinical Microbiology Reviews.
[80] R. Willcox. Ampicillin (“Penbritin”) in the Treatment of Gonorrhoea* , 1963, The British journal of venereal diseases.
[81] H. Chambers. Penicillins and β-Lactam Inhibitors , 2010 .
[82] M. Zervos,et al. Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. , 1987, Annals of internal medicine.
[83] M. Gilmore,et al. Enterococcus Diversity, Origins in Nature, and Gut Colonization , 2014 .